@article{10.37349/en.2023.00024,
abstract = {Aim: Apolipoprotein E (ApoE) isoforms, especially the ApoE4 isoform, are genetic risk factors for Alzheimer’s disease (AD). Moreover, the APOE ε4 haplotype has a dose-dependent association with an increased risk of amyloid-related imaging abnormalities (ARIA) in individuals receiving disease-modifying therapy for AD. Therefore, the importance of APOE genotyping or proteotyping has been highlighted. Here, the authors developed fully automated chemiluminescence enzyme-immunoassay kit for ApoE4 and PanApoE, and evaluated their diagnostic concordance with the APOE genotyping. Methods: One hundred seventy-eight specimens were analyzed using the Lumipulse® G ApoE4 and PanApoE for the ApoE proteotype and evaluated its diagnostic concordance with the APOE genotype. Results: The ApoE4 kit specifically detected the ApoE4 concentration in plasma samples, and the polymorphism could be classified clearly by the ratio of ApoE4 and Pan-ApoE amount in plasma. Conclusions: The combination of Pan-ApoE and ApoE4-specific chemiluminescent enzyme immunoassay (CLEIA) assay is useful for predicting APOE ε4 allele status.},
author = {Yuri, Tatsushi and Degrieck, Rosina and Minczakiewicz, Dagmara and Sato, Hideo and Kamada, Jo and Nakazawa, Takuya and Vandenbroucke, Ina and Aoyagi, Katsumi and Nojima, Hisashi},
doi = {10.37349/en.2023.00024},
journal = {Exploration of Neuroscience},
pages = {238--244},
title = {{Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE® assays}},
url = {https://www.explorationpub.com/Journals/en/Article/100624},
volume = {2},
year = {2023}
number = {5}
}